CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Ixazomib (dose not specified in this rollover protocol)AI-extracted
Key inclusion· 5
  • ✓Previously treated with ixazomib, background therapy, and/or comparator drugs in a Takeda-sponsored ixazomib parent study
  • ✓Currently on ixazomib monotherapy, ixazomib combination, placebo combination, or alternative arm regimen in a designated parent study
  • ✓Parent study is closed or planned to be closed
  • ✓In investigator's opinion, participant may benefit from continued treatment and has no alternate means to access the study drug(s)
Key exclusion· 2
  • ✕Meets any criteria for treatment discontinuation in parent study
  • ✕Pregnant or breastfeeding

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02924272
NCT02924272Phase 2Completed
CompareCT.gov

An Open-Label, Rollover Protocol for Patients Previously Enrolled in Takeda-Sponsored Ixazomib Studies

Takeda·interventional·Posted Oct 5, 2016·Updated Mar 12, 2025

In Brief

A Phase 2 clinical trial evaluating Ixazomib for Multiple Myeloma and 2 related conditions. Completed, enrolled 32 participants across 26 sites in 11 countries.

Detailed Summary

The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Lymphoma, Amyloidosis
CountriesBelgium, Canada, China, Greece, Japan, Poland, Singapore, South Korea, Spain, Sweden, United States
CollaboratorsTakeda Development Center Americas, Inc.

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 5, 2016
Enrollment StartDec 16, 2016
Primary CompletionJul 3, 2024
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 9.7 years ago

Interventions

Ixazomibdrug

Ixazomib Capsules